

25. De Boer AG, Breimer DD. The blood-brain barrier: implications for drug delivery to the brain. *J R Coll Physicians Lond* 1994; 28 (6): 502-6
26. Bradbury MWB. The blood-brain barrier. *Exp Physiol* 1993; 78: 453-72
27. Reese TS, Karnovsky MJ. Fine structural localisation of a blood-brain barrier to exogenous peroxidase. *J Cell Biol* 1967; 34: 207-17
28. Bonati M, Kanto J, Tognoni G. Clinical pharmacokinetics of cerebrospinal fluid. *Clin Pharmacokinet* 1982; 7: 312-35
29. Brodie B, Kurtz H, Schanker L. The importance of dissociation constant and lipid solubility in influencing the passage of drugs into the cerebrospinal fluid. *J Pharmacol Exp Ther* 1960; 130: 20-5
30. Crone C. The permeability of brain capillaries to non-electrolytes. *Acta Physiol Scand* 1965; 64: 407-17
31. Van Bree JBM, DeBoer AG, Danhof M, et al. Characterisation of an 'in vitro' blood brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. *J Pharmacol Exp Ther* 1988; 247 (3): 1233-9
32. Joo F, Klatzo I. Role of cerebral endothelium in brain oedema. *Neurol Res* 1989; 11: 67-75
33. Bullock R, Fujisawa H. The role of glutamate antagonists for the treatment of CNS injury. *J Neurotrauma* 1992; 9 Suppl. 2: 443-61
34. Benzel EC, Gross CD, Hadden TA, et al. The apnea test for determination of brain death. *J Neurosurg* 1989; 71: 191-4
35. Berger AJ, Mitchell RA, Severingham JW. Regulation of respiration: part I. *N Engl J Med* 1977; 297 (2): 92-7
36. Berger AJ, Mitchell RA, Severingham JW. Regulation of respiration: part II. *N Engl J Med* 1977; 297 (3): 138-43
37. Berger AJ, Mitchell RA, Severingham JW. Regulation of respiration: part III. *N Engl J Med* 1977; 297 (4): 194-201
38. Nunn JF. Control of breathing. Nunn's applied respiratory physiology. 4th ed. London: Butterworth, 1993: 90-116
39. Cohn MA. Hypnotics and the control of breathing: a review. *Br J Clin Pharm* 1983; 16 Suppl.: 245-50
40. Olson KR, Pentel PR, Kelley MT. Physical assessment and differential diagnosis of the poisoned patient. *Med Toxicol* 1987; 2: 52-81
41. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurological disorders. *N Engl J Med* 1994; 330 (9): 613-20
42. Mandema JW, Danhof M. Electroencephalogram effect measures and relationship between pharmacokinetics and pharmacodynamics of centrally acting drugs. *Clin Pharmacokinet* 1992; 23 (3): 191-215
43. Powner DJ. Drug associated isoelectric EEGs: a hazard in brain-death certification. *JAMA* 1976; 236: 1123
44. Setzer N. Brain death: physiologic definitions. *Crit Care Clin* 1985; 1 (2): 375-96
45. Taylor MJ, Houston BD, Lowry NJ. Recovery of auditory brainstem responses after a severe hypoxic ischaemic insult. *N Engl J Med* 1983; 309: 1169-70
46. Levine SR, Brust JCM, Furtell N, et al. Cerebrovascular complications of the use of the 'crack' form of alkaloidal cocaine. *N Engl J Med* 1990; 3 23: 699-704
47. Buchtal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlation with serum levels of diphenylhydantoin. *Arch Neurol* 1960; 2: 624-30
48. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. *Arch Neurol* 1974; 31 (5): 289-94
49. Ingelfinger JA, Isakson G, Shine D, et al. Reliability of the toxic screen in overdose. *Clin Pharmacol Ther* 1981; 29 (5) 570-95
50. Spiechler VR, O'Donnell CM, Gokhale DV. Confirmation and certainty in toxicology screening. *Clin Chem* 1988; 34 (8) 1535-9
51. Op de Coul AAW, Lambregts PCLA, Koeman J, et al. Neuromuscular complications in patients given Pavulon® (pancuronium bromide) during artificial ventilation. *Clin Neurol Neurosurg* 1985; 87 (1): 17-22
52. Belaesky M, Kalwans HI. Prolonged neuromuscular blockade with pancuronium bromide in a young healthy woman. *Anaesthesiology* 1971; 40 (3): 295-6
53. Segredo V, Caldwell JE, Marthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. *N Engl J Med* 1992; 327: 524-8
54. Tyson RN. Simulation of cerebral death by succinylcholine sensitivity. *Arch Neurol* 1974; 30: 409-11
55. Shapiro HM. Barbiturates in brain ischaemia. *Br J Anaesth* 1985; 57: 82-95
56. Scatton B, Carter C, Benavides J, et al. N-Methyl-D-Aspartate receptor antagonists: a novel therapeutic perspective for the treatment of ischaemic brain injury. *Cerebrovasc Dis* 1991; 1: 121-35
57. Fitzpatrick AJ, Crawford M, Allan RM, et al. Aconite poisoning managed with a ventricular assist device. *Anaesth Intensive Care* 1994; 22: 714-7

Correspondence and reprints: Dr *Michael Kennedy*, Level 4, 22 Darley Rd, Manly, NSW 2095, Australia.

Erratum

Vol. 13, No. 4, page 239, figure 2: Under section Chatelut et al. the formula should read 'Carboplatin clearance (ml/min) = $\frac{0.314}{\text{bodyweight (kg)}}$ × ...' not 0.134.

[McKeage MJ. Comparative adverse effect profiles of platinum drugs. *Drug Saf* 1995 Oct; 14 (4): 228-244]